NPPA panel rejects Cadila Healthcare retail price fixation application for Tacrolimus PR capsules Susmita Roy17 April 2022 6:30 AMNew Delhi: Citing that the Central Drugs Standard Control Organisation(CDSCO) has not given approval to Cadila Healthcare to import and manufacture...
Cadila gets CDSCO panel nod to manufacture, market Calcium Polystyrene Sulphonate suspension Medical Dialogues Team16 Nov 2021 1:27 PMNew Delhi: Pharmaceutical major Cadila Healthcare has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drugs...
Cadila Healthcare gets CDSCO panel okay for Fluticasone Furoate, Oxymetazoline HCL nasal spray Medical Dialogues Team19 July 2021 7:30 AMNew Delhi: In a major rejoice for pharma major Cadila Healthcare, the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
NPPA Panel suggests Price Of Cadila Healthcare Dexamethasone in 5 strengths Medical Dialogues Team28 April 2021 1:31 PMNew Delhi: The National Pharmaceutical Pricing Authority (NPPA) Committee has suggested the retail price of each uncoated tablet containing...
Submit 28 days trial results of Hepatitis C drug for Covid-19: CDSCO panel to Zydus Cadila Medical Dialogues Team21 April 2021 5:42 AMNew Delhi: In response to the drug major Zydus Cadila's proposal for marketing authorisation of the Hepatitis C drug, Pegylated Interferon Alpha-2b...
NPPA directs Cipla, Sun Pharma, others to reduce Remdesivir MRP Medical Dialogues Team17 April 2021 10:43 AMNew Delhi: With the demands of Covid-19 drug Remdesivir shooting up, the National Pharmaceutical Pricing Authority (NPPA) has directed drugmakers...
Cadila Healthcare gets CDSCO panel go-ahead for Phase 3 trial of Novel Corona Virus 2019-nCoV Vaccine MD Bureau7 Jan 2021 11:58 AMNew Delhi: Pharmaceutical major, Cadila Healthcare has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
Phase 1 trials of 2 indigenous COVID Vaccines reveal excellent safety: Minister Ruchika Sharma16 Sept 2020 5:30 AMNew Delhi: Phase-I clinical trials have revealed "excellent safety" of the two candidate vaccines indigenously developed by Bharat Biotech in...
